****EVENT DRIVEN TRADERS' BOARD****

[adijas]

ACXA website new owner Medisun http://www.medisun.hk/index.php?route=common/home

ABOUT MEDISUN

Medisun Holdings Limited, with its headquarters in Hong Kong, is a global professional medical investment group that focuses on investing in research, development and commercialization of regenerative medicine and top-tier hospitals and medical centers. Medisun has invested in Cardio3 BioSciences, a Belgian and French stock exchange-listed biotechnology company. Medisun is also actively engaged in clinical development of regenerative therapies in the United States, Japan, Hong Kong and China. Medisun has brought in the products and technologies invented by Mayo Clinic from the United States. Medisun owns a variety of clinical proprietary stem cell therapy technologies, including C-Cure®, a product in Phase III development in Europe and the US to treat ischemic heart failure. C-Cure® could be launched first in Europe in 2017. Medisun Holdings and Mayo Clinic signed a master healthcare agreement in 2015, and the two parties will carry out a multifaceted, innovative collaboration advancing healthcare delivery in Hong Kong and mainland China.